Development and in vitro evaluation of temozolomide-loaded PLGA nanoparticles in a thermoreversible hydrogel system for local administration in glioblastoma multiforme

Basit Öğe Kaydı
dc.authoridEsendagli, Gunes/0000-0003-4865-2377
dc.authoridARISOY, SEMA/0000-0003-2798-1884
dc.authoridARISOY, SEMA/0000-0003-2798-1884
dc.authoridOzbay Kurt, Feyza Gul/0000-0003-4086-6469
dc.authorwosidEsendagli, Gunes/Q-5136-2019
dc.authorwosidARISOY, SEMA/ABI-2760-2020
dc.authorwosidARISOY, SEMA/V-1458-2017
dc.contributor.authorSayiner, Ozgun
dc.contributor.authorArisoy, Sema
dc.contributor.authorComoglu, Tansel
dc.contributor.authorOzbay, Feyza Gul
dc.contributor.authorEsendagli, Gunes
dc.date.accessioned2024-08-04T20:47:12Z
dc.date.available2024-08-04T20:47:12Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractWith its ability to cross the blood-brain barrier, temozolomide (TMZ) is the first-line treatment option in glioblastoma multiforme therapy. This study aims to design TMZ-loaded PLGA nanoparticles (TMZ-PLGA-NP) in a thermoreversible hydrogel system comprising Pluronic (R) F-127. TMZ-PLGA-NP were prepared via emulsion-solvent evaporation method using dimethylformamide (DMF) as organic solvent and PVA solution as stabilizer. Experimental parameters for the formulation process and in vitro release profiles of free drug, TMZ-PLGA-NP and TMZ-PLGA-NP-loaded in hydrogel were investigated. Particle size in the range of 100-200 nm with an encapsulation efficiency of 55-70% has been obtained. In vitro studies showed that the TMZ-PLGA-NP loaded in hydrogel formulations have significantly slowed down the release process, providing controlled and sustained release. These nanoparticles were efficiently taken up by the glioblastoma cells and the TMZ released from the TMZ-PLGA-NP-loaded in hydrogel could reach to the efficiency of direct exposure to the free-drug. In conclusion, the thermoreversible hydrogel system containing TMZ-loaded PLGA nanoparticles may serve as a promising approach that could sustain long-term drug release for the treatment of residual glial tumors after surgery.en_US
dc.description.sponsorshipBAP (Scientific Research Projects Department of Ankara University) [18L0237003]en_US
dc.description.sponsorshipThis study was supported by BAP (Scientific Research Projects Department of Ankara University; Project No: 18L0237003).en_US
dc.identifier.doi10.1016/j.jddst.2020.101627
dc.identifier.issn1773-2247
dc.identifier.issn2588-8943
dc.identifier.scopus2-s2.0-85080110421en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.jddst.2020.101627
dc.identifier.urihttps://hdl.handle.net/11616/99203
dc.identifier.volume57en_US
dc.identifier.wosWOS:000538406300012en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal of Drug Delivery Science and Technologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTemozolomideen_US
dc.subjectThermoreversibleen_US
dc.subjectHydrogelen_US
dc.subjectNanoparticleen_US
dc.subjectBrain deliveryen_US
dc.subjectGlioblastoma multiformeen_US
dc.titleDevelopment and in vitro evaluation of temozolomide-loaded PLGA nanoparticles in a thermoreversible hydrogel system for local administration in glioblastoma multiformeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu